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The angiotensin-converting enzyme (ACE) gene is a potential candidate gene for risk of
asthma, COPD, and COPD co-morbidity. In 9034 Danish adults, we determined whether individ-
uals homozygous or heterozygous for the ACE D allele are at greater risk of asthma, COPD, or
COPD co-morbidity compared with ACE II homozygous individuals. In the general population,
serum ACE activity increased with the number of D alleles (Kruskal-Wallis ANOVA: II vs. ID,
p< 0.001; ID vs. DD, p< 0.001); however, this did not translate into altered risk of asthma
or COPD. In the general population, the odds ratio (95% confidence interval) for asthma was
1.2 (0.9e1.4) for ID individuals and 1.2 (0.9e1.5) for DD individuals compared with II individ-
uals. In the general population, the odds ratio for COPD was 0.9 (0.8e1.1) for ID individuals and
1.0 (0.8e1.2) for DD individuals compared with II individuals. Among patients with COPD, the
odds ratio for ischemic heart disease was 1.1 (0.8e1.6) for ID individuals and 1.2 (0.8e1.7) for
DD individuals compared with II individuals; corresponding odds ratios for hypertension were
1.1 (0.7e1.5) and 0.8 (0.5e1.2), and for low physical activity 0.9 (0.5e1.4) and 0.7
(0.4e1.2). The results were similar upon adjustment for sex, age, smoking status, body mass
index, total cholesterol, and ACE inhibitor/angiotensin II type 1 receptor blocker use. These
data suggest that lifelong genetically elevated ACE activity is not a major risk factor for asthma
or COPD, or for ischemic heart disease, hypertension, and low physical activity in COPD
patients.
ª 2009 Elsevier Ltd. All rights reserved.88 3846; fax: þ45 4488 3311.
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The World Health Organization (WHO) lists chronic
obstructive pulmonary disease (COPD) as the fifth most
common cause of death, constituting some five percent
of the total deaths in 2003.1 This number is expected to
rise in the near future with the current increase in.
Asthma, COPD and COPD co-morbidity by ACE genotype 1287tobacco consumption in the third world being of major
concern.
COPD is characterized by an abnormal excessive
inflammatory response of the lung parenchyma to inhaled
irritants and toxins, and by the presence of systemic
inflammation.2 The most important risk factor for devel-
opment of COPD is tobacco smoking. It is well known that
COPD patients often suffer from ischemic heart disease
(IHD) and hypertension, and one study suggests that the risk
for cardiovascular illness in COPD is associated with severity
of the underlying pulmonary disease.3 Although respiratory
failure is the predominant cause of death in patients with
advanced COPD (GOLD stages III and IV), cardiovascular
disease is one of the main causes of mortality in milder
cases. Furthermore, progression of disease in COPD may be
promoted by low physical activity, which frequently occurs
in COPD patients due to loss of skeletal muscle strength.4
The angiotensin-converting enzyme (ACE) gene is one
potential candidate gene for risk of asthma,5 COPD,6 and
co-morbidity in COPD.7e9 The primary function of ACE is the
conversion of angiotensin I to angiotensin II. This oligo-
peptide is in itself a potent vasoconstrictor with speculated
involvement in the development of primary hyperten-
sion,10,11 however, angiotensin II also mediates biosynthesis
of growth factors and might, thus, modulate the develop-
ment of cachexia,12 and impaired physical capability in
COPD patients.
Clinical trials where modulators of the renin-angiotensin
system (ACE inhibitors and angiotensin II type 1 receptor
blockers) were administered to COPD patients have indi-
cated that medically reduced angiotensin II synthesis is
beneficial in these patients.7,9 These studies showed not
only lowered incidence of cardiovascular co-morbidity, but
also reduced hospitalisation and mortality due to COPD. It is
therefore likely that genetically altered ACE activity could
affect risk of cardiovascular co-morbidity in COPD patients.
A well-characterized variation of the ACE gene defined
by the absence (Deletion, D allele) vs. presence (Insertion, I
allele) of a 287 base-pair fragment in intron 16 is associated
with increased ACE activity,13e15 and consequently with
raised levels of angiotensin II and other vasoactive
substances.15,16
Using data from The Copenhagen City Heart Study,
a prospective general population study, Agerholm-Larsen
et al. previously showed that the ACE genotype increases
ACE activity, but not the risk of ischemic heart disease.14,17
In the present study, we test the hypothesis that individuals
homozygous or heterozygous for the ACE D allele vs. II




We studied individuals who participated in the third
examination of The Copenhagen City Heart Study from 1991
through 1994. This prospective general population study
includes an almost equal number of women (55%) and men
stratified into 10-year age groups from 20 to 80 years old.
Of 10,049 participants (response rateZ 58%), 9034 had ACEI/D genotype determined and were Caucasians of Danish
descent.17 All participants gave written, informed consent,
and Herlev Hospital, Copenhagen University Hospital and
the ethics committee for Copenhagen and Frederiksberg
approved the study (Study no. 100.2039/91). Details of the
selection procedure, examination program, and study
subjects have been presented elsewhere.18,19
Asthma
The presence of asthma was defined by an affirmative
response to the question: ‘‘Do you have asthma?’’ If the
definition of asthma assumed asthma medicines or was an
affirmative answer to the question ‘‘Does exposure to food,
medicine, flowers, animals or anything else cause
asthma?’’, the results were similar to those presented
(Table 1 in supplementary).
COPD
A dry wedge spirometer (Vitalograph; Maids Moreton,
Buckinghamshire, UK) was used to obtain FEV1 and FVC
values; the spirometer was calibrated daily with a 1-L
syringe. Three sets of values with two measurements
differing by less than 5% were obtained. The highest
measurements of FEV1 and FVC were used in the analyses as
absolute values and as percentages of predicted values
using internally derived reference values based on
a subsample of healthy never-smokers.20,21 We used an
equal number of subjects in the subgroups for the calcu-
lation of percentage predicted values. COPD was defined as
an FEV1 to FVC ratio of less than 0.7 and FEV1 of less than
80% of the expected value, excluding those with self-
reported asthma (Global Initiative for Chronic Obstructive
Lung Disease (GOLD) stages II through IV). Out of the 1259
individuals identified with COPD, 314 had GOLD stage II, 609
GOLD stage III, and 336 GOLD stage IV. If the statistical
analyses concerning COPD were stratified according to
GOLD stages (Tables 2 and 3 in supplementary), the results
were similar to those presented. Individuals with self-
reported asthma were excluded from the COPD definition,
but had spirometry and all other analyses performed.
Ischemic heart disease
Ischemic heart disease (IHD) diagnoses (ICD8: 410e414 and
ICD10: I20eI25) were obtained from the Danish National
Hospital Discharge Registry. This registry covers all patients
discharged from a hospital in Denmark with IHD as either
primary or secondary indication for hospitalisation.
Hypertension
Blood pressure was measured by trained technicians using
the London School of Hygiene sphygmomanometer on the
left arm after 5 min rest with the subject in the sitting
position. The fifth Korotkoff sound was used for diastolic
pressure. The fall of the mercury column was set to 2 mm/s.
The blood pressure cuff was 12 26 cm, but for subjects
with an upper arm circumference of >46 cm, a cuff that
measured 15 38 cm was used. Inter-observer variation
1288 J. Lee et al.was tested and found to be statistically insignificant.
Hypertension was defined as systolic blood pressure of
140 mmHg, diastolic blood pressure of 90 mmHg,22
and/or treatment with antihypertensive medication.
Low physical activity
The Copenhagen City Heart Study Leisure Time Physical
Activity Questionnaire was used to assess physical activity
during leisure time within the past year.23 Subjects repor-
ted whether they were 1) almost completely sedentary or
did light physical activity less than 2 h per week (e.g.
reading, watching television or movies), 2) did light phys-
ical activity 2e4 h per week (e.g. walking, biking, light
gardening, light sports), 3) did light physical activity more
than 4 h per week or more vigorous activity for 2e4 h per
week (e.g. brisk walking, fast biking, heavy gardening,
sports that cause perspiration or exhaustion), or 4) did
highly vigorous physical activity more than 4 h per week or
regular heavy exercise or competitive sports several times
per week. Low physical activity was defined as an overall
activity level of less than 4 h per week (groups 1 and 2).
Supporting the validity of the questions, higher levels of
resting heart rate, body mass index, and plasma lipids were
associated with report of reduced physical activity during
leisure time. The questionnaire is based on a Swedish
questionnaire, which has been validated against maximal
oxygen uptake in 20e42 year old men (maximal oxygen
uptake increased with report of increased physical activity
during leisure time).23
Other covariates
Smoking status was reported as ‘‘current smoker’’, ‘‘ex-
smoker’’, or ‘‘never-smoker’’. Body mass index (BMI) was
weight (kg) divided by height squared (m2).
Laboratory measurements
Serum ACE activity was determined kinetically at 340 nm
utilizing the tripeptide N-(3-(2-furyl)acryloyl)-L-phenyl-
alanylglycylglycine (FAPGG) as the substrate (Sigma, St.
Louis, MO, USA). Serum ACE activity was measured in 834
randomly selected subjects14; Out of these, 117 had COPD,
while 717 had no COPD. Cholesterol was measured enzy-
matically (Boehringer Mannheim).
The insertion/deletion polymorphism of 287 bp in intron
16 of the ACE gene was identified by conventional poly-
merase chain reaction (PCR) using two primers flanking the
site of the insertion.17 Because the D allele in heterozy-
gotes is amplified preferentially, probably due to its smaller
size, all samples apparently homozygous for the D allele
were subjected to a second PCR amplification with an
insertion-specific primer.24
Statistical methods
Statistical analyses were performed using Stata/SE v.10
(StataCorp LP, 4905 Lakeway Drive College Station, Texas
77845, USA). A p-value of <0.05 on a two-sided test was
considered significant. Pearson’s c2-test was used to testfor differences in the distribution of percentage of females,
smokers, and asthma cases across genotypes. Kruskal-Wallis
analysis of variance (ANOVA) was used to test for differ-
ences in medians of age, BMI, total cholesterol, lung
function, and serum ACE activity between the three geno-
types; the Mann-Whitney U-test was used for post hoc pair-
wise comparisons between genotypes. Logistic regression
analysis was used to calculate odds ratios for all endpoints
according to ACE genotype. Adjusted odds ratios were
obtained by including age, smoking, BMI, total cholesterol,
and ACE inhibitor/angiotensin II type 1 receptor blocker use




Clinical characteristics did not differ between subjects with
the three different genotypes (Table 1); total cholesterol
was slightly higher in II than in ID and DD individuals,
however, this result did not reach statistical significance
after correction for seven multiple comparisons.
The relative genotype frequencies were 24% for II, 50%
for ID, and 26% for DD. This was in accordance with the
Hardy-Weinberg equilibrium (c2-test: pZ 0.53) and corre-
sponds well with the findings of others.25
Among COPD patients, clinical characteristics did not
differ according to the three different genotypes; p-values
for the distribution of age and FEV1% predicted became
insignificant after correction for six multiple comparisons.
As expected, COPD patients were older, more likely
smokers, and had consistently lower FEV1% predicted than
those without COPD (data not shown). The high number of
COPD subjects may be due to the high prevalence of ever
smokers in the population.
ACE genotype and serum ACE activity
Serum ACE activity was measured in a subsample of 834
randomly selected participants and 117 out of these had
COPD (Fig. 1). The ACE activity for the three genotypes was
found to increase with the number of D alleles. Among
individuals without COPD (nZ 717) median activities
(inter-quartile range, IQR) were 21 U/L (19e25 U/L) for II,
27 U/L (23e32 U/L) for ID, and 34 U/L (30e42 U/L) for DD
individuals (Kruskal-Wallis ANOVA: p< 0.001, pII-ID< 0.0001,
pID-DD< 0.0001, pII-DD< 0.0001). The corresponding numbers
for COPD patients (nZ 117), were 22 U/L (20e26 U/L),
27 U/L (24e33 U/L), and 36 U/L (33e40 U/L) (Kruskal-
Wallis ANOVA: p< 0.001, pII-ID< 0.001, pID-DD< 0.001,
pII-DD< 0.0001).
ACE genotype and risk of asthma and COPD
Among the 9034 study subjects, 602 had asthma and 1259
suffered from COPD. The odds ratio for asthma was 1.2
(0.9e1.4) for ID and 1.2 (0.9e1.5) for DD compared with II
individuals (Table 2). For COPD, odds ratios were 0.9
(0.8e1.1) for the ID genotype and 1.0 (0.8e1.2) for the DD
genotype. Adjustment for sex, age, smoking status, BMI,
Table 1 Baseline characteristics of study subjects from the general population.
ACE genotype All (nZ 9034) COPDa (nZ 1259)
II ID DD pb II ID DD pb
n 2175 4485 2374 314 609 336
Females, % 55 56 56 0.89 46 50 51 0.38
Age, years 46 (38e54) 46 (37e54) 46 (38e55) 0.77 50 (43e56) 51 (45e58) 50 (43e57) 0.02c
Ever smokers, % 76 75 74 0.35 88 85 89 0.32
Body mass index,
kg/m2
24 (22e27) 24 (22e27) 24 (22e27) 0.47 24 (22e27) 24 (22e27) 24 (22e26) 0.13
Total cholesterol,
mmol/L
5.8 (5.1e6.6) 5.7 (5.0e6.5) 5.7 (5.0e6.6) 0.02c 5.8 (5.2e6.5) 6.0 (5.3e6.7) 6.0 (5.2e6.6) 0.11
FEV1, % of predicted 89 (79e99) 89 (79e99) 89 (80e99) 0.78 75 (65e84) 74 (65e84) 76 (68e87) 0.03
c
Asthma,d % 6 7 7 0.24 NR NR NR
Values represent number of individuals, percentages or median (inter-quartile range).
a Chronic obstructive pulmonary disease (COPD)Z FEV1/FVC< 0.7 and FEV1% predicted< 80%, excluding those with asthma.
b p-values by Kruskal-Wallis ANOVA and c2-test.
c After correction for multiple comparisons, these results did not reach statistical significance.
d AsthmaZ affirmative to the question ‘‘Do you suffer from asthma?’’. ACEZ angiotensin-converting enzyme; FEV1Z forced expi-
ratory volume in one second; II, ID, and DDZ non-carrier, heterozygous, and homozygous carrier of the ACE insertion-deletion poly-
morphism, respectively. NRZ not relevant as those with asthma were excluded among COPD patients.
Figure 1 Serum angiotensin-converting enzyme (ACE)
activity by ACE genotype. II, ID, and DDZ non-carrier,
heterozygous, and homozygous carrier of the ACE insertion-
deletion polymorphism, respectively. COPD: nZ 117; no COPD:
nZ 717; *p< 0.001; **p< 0.0001.
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inhibitor/angiotensin II type 1 receptor blocker use
provided similar odds ratios.
ACE genotype, ischemic heart disease,
hypertension, and low physical activity in COPD
patients
Among the 1259 COPD patients, 284 had been hospitalised
for IHD. The odds ratio (95% confidence interval, CI) for IHD
hospitalisation was 1.1 (0.8e1.6) for ID and 1.2 (0.8e1.7)
for DD compared with II individuals (Table 3). These results
were similar upon adjustment for sex, age, smoking status,
BMI, total cholesterol, and angiotensin-converting enzyme
(ACE) inhibitor/angiotensin II type 1 receptor blocker use.
Also, of the 1259 COPD patients, 522 were hypertensive.
The odds ratio for hypertension was 1.1 (0.7e1.5) for ID and
0.8 (0.5e1.2) for DD compared with II individuals (Table 3).
These results were similar upon adjustment for sex, age,
smoking status, BMI, total cholesterol, and angiotensin-
converting enzyme (ACE) inhibitor/angiotensin II type 1
receptor blocker use.
Finally, of the 1259 COPD patients, 505 subjects had low
physical activity level. The odds ratio for low physical
activity was 0.9 (0.5e1.4) for ID and 0.7 (0.4e1.2) for DD
compared with II individuals (Table 3). These results were
similar upon adjustment for sex, age, smoking status, BMI,
total cholesterol, and angiotensin-converting enzyme (ACE)
inhibitor/angiotensin II type 1 receptor blocker use.
Discussion
It has consistently been found that the D allele is associated
with increased serum ACE activity25 and thus, higher levels
of circulating vasoactive peptides and inflammatory factors
such as angiotensin II, substance P, and neurokinin A.
Conceivably, this would imply a role for ACE genotype in
Table 2 Risk of COPD or asthma in 9034 individuals from the general population by ACE genotype.
ACE genotype Asthmaa (nZ 602) COPDb (nZ 1259)
II ID DD II ID DD
Crude 1.00 1.2 (0.9e1.4) 1.2 (0.9e1.5) 1.00 0.9 (0.8e1.1) 1.0 (0.8e1.2)
Adjustedc 1.00 0.8 (0.4e1.4) 0.6 (0.3e1.2) 1.00 1.0 (0.6e1.5) 0.8 (0.5e1.3)
Values represent odds ratios and 95% confidence intervals.
a AsthmaZ affirmative to the question ‘‘Do you suffer from asthma?’’.
b Chronic obstructive pulmonary disease (COPD)Z FEV1/FVC< 0.7 and FEV1% predicted< 80%, excluding those with asthma.
c Adjusted for sex, age, smoking status, body mass index, total cholesterol, and angiotensin-converting enzyme (ACE) inhibitor/
angiotensin II type 1 receptor blocker use. II, ID, and DDZ non-carrier, heterozygous, and homozygous carrier of the ACE insertion-
deletion polymorphism, respectively.
1290 J. Lee et al.pathologies that involve inflammation, such as cardiovas-
cular disease, asthma, and COPD.6,26e28 Pharmacological
studies support a role for ACE in development of cardio-
vascular co-morbidities in COPD patients. To our knowl-
edge, no larger studies have previously addressed the
potential influence of ACE genotype on risk of IHD, hyper-
tension, or low physical activity in COPD patients.
Risk of asthma and COPD in the general population
Since ACE genotype affects ACE activity and hence modu-
lates the levels of inflammatory factors, carriers of the D
allele could conceivably experience an excessive inflam-
matory response to inhaled irritants, and therefore be at
higher risk for chronic inflammatory lung disease than non-
carriers.
Reports on the involvement of ACE in the risk of asthma
are somewhat conflicting. The findings are mainly negative,
reporting no association of ACE genotype with risk or
severity of asthma.28,29 This is contradicted by a French
study, which concludes that ACE DD genotype is indeed
associated with asthma independent of degree of airway
obstruction.5 The bulk of the evidence does, however,
point to no association, which is also confirmed in our large
study population.
The available literature on ACE genotype in relation to
risk of COPD is very limited, but in a small study from 2007,
Busquets et al. found evidence of an association of ACE I/D
genotype with smoking history and risk of developing
COPD.6 Our study did not reveal any such association with
COPD GOLD stages II, III, and IV analysed separately or
combined.Table 3 Risk of co-morbidity in 1259 COPD patients by ACE gen
ACE genotype IHD (nZ 284) Hypertensio
II ID DD II ID
Crude 1.00 1.1 (0.8e1.6) 1.2 (0.8e1.7) 1.00 1.1 (0
Adjusteda 1.00 1.0 (0.4e2.4) 1.3 (0.5e3.4) 1.00 1.0 (0
Values represent odds ratios and 95% confidence intervals.
a Adjusted for sex, age, smoking status, body mass index, total c
angiotensin II type 1 receptor blocker use. IHDZ ischemic heart dis
DDZ non-carrier, heterozygous, and homozygous carrier of the ACEIschemic heart disease and hypertension in
COPD patients
Although previous studies suggest no direct effects of ACE
genotype on either IHD or hypertension in the general
population,17,24,25 other studies point to potential impor-
tance in certain subgroups of individuals. In 2007, Muthu-
mala et al.26 reported that the D allele had a protective
effect against development of coronary heart disease in
middle-aged hypertensive men through a supposed modu-
latory effect on systolic blood pressure. However, analo-
gous to the findings for healthy individuals, our results do
not indicate any association between ACE genotype and risk
of cardiovascular complications in COPD.
Low physical activity in COPD patients
Maintaining a moderate level of physical activity is benefi-
cial to the prognosis of COPD. However, physical capacity
becomes gradually impaired in individuals suffering from
the disease. This is particularly due to quadriceps weakness
which is a marked complication of COPD.30 The effect of
ACE genotype on exercise capacity has been assessed in
both healthy subjects and COPD patients. Intriguingly, the
effect of the D allele seems to be positively correlated with
muscle strength in COPD patients,8 whereas it has been
consistently shown to be negatively associated with muscle
strength in healthy subjects.31,32 A somewhat different
mechanism for impaired exercise capacity due to the ACE
DD genotype is proposed by Kanazawa et al.,27 who find
that this genotype is associated with exaggerated pulmo-
nary hypertension and disturbance in tissue oxygenationotype.
n (nZ 522) Low physical activity (nZ 505)
DD II ID DD
.7e1.5) 0.8 (0.5e1.2) 1.00 0.9 (0.5e1.4) 0.7 (0.4e1.2)
.7e1.4) 0.9 (0.6e1.3) 1.00 0.9 (0.5e1.4) 0.7 (0.4e1.2)
holesterol, and angiotensin-converting enzyme (ACE) inhibitor/
ease; COPDZ chronic obstructive pulmonary disease; II, ID, and
insertion-deletion polymorphism, respectively.
Asthma, COPD and COPD co-morbidity by ACE genotype 1291during exercise. This is also proposed by Gosker et al.,32
who suggest that exercise capacity, in contrast to muscle
strength, is not associated with D in COPD, so that the I
allele is associated with enhanced improvement and/or
preservation of endurance and the D allele with better
improvement and/or preservation of muscle strength.
In our study, we, unfortunately, did not have the means
to conduct direct measurements of muscle strength nor to
administer exercise tests. Based on the subjects’ self-
reported physical activity levels during leisure time, we
tested for association of the D allele with either higher or
lower levels of physical activity among COPD patients, but
no such associations were found.
Limitations
Some degree of misclassification of asthma was possible,
since participants classified themselves; however, the
prevalence of asthma was in accordance with the reference
figures for Denmark and using alternative definitions of
asthma showed similar results. Misclassification of low
physical inactivity was also possible. However, supporting
the validity of this definition, participants who reported low
physical activity also had higher heart rate, body mass
index and serum lipid levels. Over the years, the intron 16
I/D polymorphism of the ACE gene has been the subject of
several scientific studies on individuals of various ethnic-
ities. It is speculated that ethnicity is an important factor in
determining the magnitude of the effect of genetic varia-
tion. The findings of this study are based on a large
homogenous population of Danes, all coming from the city
of Copenhagen, and the generalisability of our data may
therefore be constrained to white people only.
Conclusions
In conclusion, no association was found between the ACE I/
D genotype and risk of asthma or COPD. ACE I/D genotype
was not associated with higher prevalence of IHD or
hypertension in COPD patients. Likewise, the level of
physical activity among COPD patients showed no correla-
tion with ACE genotype. The data suggest that lifelong
genetically elevated ACE activity is not a risk factor for
asthma, COPD, or COPD co-morbidity.
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